Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy

Jennifer A Woyach,Nancy L Bartlett,Nyla A Heerema,Mark R Litzow,James S Blachly,Allison M Booth,Charles Kuzma,John C Byrd,Carolyn Owen,Scott E Smith,Gerard Lozanski,Harry P Erba,Wei Ding,Paul M Barr,Amy S Ruppert,Jeremy S Abramson,Sameer A Parikh,Richard F Little,Sreenivasa Nattam,Weiqiang Zhao,Richard A Larson,Danielle M Brander,Kerry A Rogers ,Sumithra J Mandrekar ,Richard Stone ,Jennifer R Brown ,Steven Coutré

doi:10.1182/blood-2021-153146

Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy

Jennifer A Woyach, Nancy L Bartlett + Show 25 more

Open Access

https://doi.org/10.1182/blood-2021-153146

Copy DOI

Journal: Blood	Publication Date: Nov 5, 2021
Citations: 32

Affiliation: The Ohio State University, Washington University in St. Louis, Mayo Clinic, Southeast Clinical Oncology Research Consortium, University of Cincinnati Medical Center, University of Calgary, Loyola University Medical Center, University of Alabama at Birmingham, University of Rochester, Alliance Data (United States), Massachusetts General Hospital, National Cancer Institute, FWRadiology, University of Chicago, Duke Medical Center, Dana-Farber Cancer Institute, Stanford University

#Research Funding #Advisory Committees + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Blood

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.